Holen Sie sich die Stockscreener-App
200.87
1.40%
-2.86
Vorhandelsmarkt:
200.87
Insulet Corp Aktie (PODD) Neueste Nachrichten
Is Insulet Corporation (PODD) One of the Most Oversold Healthcare Stocks to Invest In? - Yahoo Finance
Insulet Corp. stock underperforms Monday when compared to competitors - MarketWatch
Why Insulet (PODD) is a Top Growth Stock for the Long-Term - Yahoo Finance
Should You Investigate Insulet Corporation (NASDAQ:PODD) At US$204? - Moomoo
Insulet Taps Mike Panos As CCO While Shares Trade Below Targets - Yahoo Finance
Analysts see 75% upside on Insulet Corporation (PODD) despite weak share price momentum - MSN
Insulet Corp stock (US45784P1012): Is tubeless insulin delivery strong enough to unlock new upside? - AD HOC NEWS
Insulet stock (US45784P1012): Is the Omnipod edge strong enough to unlock new upside? - AD HOC NEWS
Short Interest in Insulet Corporation (NASDAQ:PODD) Rises By 19.3% - MarketBeat
Insulet Corp. stock rises Friday, still underperforms market - MarketWatch
Truist maintains Insulet Corporation (PODD) buy rating despite device correction announcement - MSN
Insulet Corporation Appoints Mike Panos as Chief Commercial Officer - HarianBasis.co
Citi Flags Competitive Pressure as Key Risk for Insulet Corporation (PODD) - Yahoo Finance
Insulet Corp. Stock Hits 52-Week Low at USD 197.63 Amid Challenges - Markets Mojo
KBC Group NV Grows Stock Position in Insulet Corporation $PODD - MarketBeat
Lbp Am Sa Grows Position in Insulet Corporation $PODD - MarketBeat
PODD Forecast, Price Target & Analyst Ratings | INSULET CORP (NASDAQ:PODD) - ChartMill
Insulet (PODD) down 8.2% since last earnings report: Can it rebound? - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet CorporationPODD - ChartMill
PODD Investor Alert: Insulet Corp. Potential Securities - GlobeNewswire
Insulet Faces Omnipod 5 Correction While Shares Trade Below Targets - Sahm
BTIG Maintains Buy Rating on Insulet (PODD) - Insider Monkey
Truist Financial Has Lowered Expectations for Insulet (NASDAQ:PODD) Stock Price - MarketBeat
PODD Investor Alert: Insulet Corp. Potential Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Device Defect: Levi & Korsinsky - Morningstar
Truist Cuts Price Target on Insulet to $315 From $360, Keeps Buy Rating - marketscreener.com
Patton Fund Management Inc. Reduces Holdings in Insulet Corporation $PODD - MarketBeat
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Evercore Reiterates Outperform Rating for Insulet Corp. (PODD) - Insider Monkey
RBC Cuts Price Target on Insulet to $325 From $380, Keeps Outperform Rating - marketscreener.com
Insulet (NASDAQ:PODD) Reaches New 1-Year Low on Analyst Downgrade - MarketBeat
BTIG Research Lowers Insulet (NASDAQ:PODD) Price Target to $320.00 - MarketBeat
BTIG Maintains Insulet(PODD.US) With Buy Rating, Cuts Target Price to $320 - Moomoo
BTIG Research Adjusts Insulet Price Target to $320 From $380, Maintains Buy Rating - marketscreener.com
Robeco Institutional Asset Management B.V. Increases Stock Position in Insulet Corporation $PODD - MarketBeat
Baillie Gifford & Co. Trims Stock Position in Insulet Corporation $PODD - MarketBeat
A Look At Insulet (PODD) Valuation After Mike Panos Joins As Chief Commercial Officer - Sahm
Liquidity Mapping Around (PODD) Price Events - Stock Traders Daily
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer - MSN
Insulet Corp. stock falls to new 52-week low - MarketWatch
Insulet stock (US45784P1012): Is its tubeless insulin tech strong enough to unlock new upside? - AD HOC NEWS
Insulet Taps Mike Panos To Drive Omnipod Commercial Execution And Growth - Yahoo Finance Australia
A Look At Insulet (PODD) Valuation After Recent Share Price Weakness - Yahoo Finance
New Commercial Chief and Closed-Loop Progress Might Change The Case For Investing In Insulet (PODD) - simplywall.st
Analysts See 75% Upside on Insulet Corporation (PODD) Despite Weak Share Price Momentum - Insider Monkey
Insulet stock: What investors need to know amid diabetes tech boom - AD HOC NEWS
Insulet Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Insulet Corp. Hits 52-Week Low at USD 199.53 Amid Market Challenges - Markets Mojo
Goldman Sachs Adjusts Price Target on Insulet to $277 From $326, Maintains Buy Rating - marketscreener.com
Insulet Corporation (NASDAQ:PODD) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Insulet Corporation stock hits 52-week low at 199.53 USD By Investing.com - Investing.com Australia
Insulet Corporation (PODD) Stock forecasts - Yahoo Finance UK
Insulet (PODD) Gets Downgraded by Citigroup; Price Target Lowere - GuruFocus
Insulet (PODD) Gets Downgraded by Citigroup; Price Target Lowered | PODD Stock News - GuruFocus
Insulet (PODD) Appoints Mike Panos as Chief Commercial Officer - Insider Monkey
Insulet Corporation stock hits 52-week low at 199.53 USD - Investing.com
Insulet (NASDAQ:PODD) Cut to Neutral at Citigroup - MarketBeat
Citigroup Downgrades Insulet to Neutral From Buy, Adjusts Price Target to $230 From $338 - Moomoo
Citi Downgrades Insulet Corporation (PODD) to Neutral - StreetInsider
0.74%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):